Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABSI vs NOVTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABSI Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–2 Matrix Metrics)

ABSI Overall Winner 6-Pillar Tally: ABSI 4 – 0 NOVTU (2 Tie) Matrix Metrics: ABSI 6 – 2 NOVTU

As of Nov 16, 2026, Absci Corporation (ABSI) is the stronger overall head-to-head candidate over NOVTU (NOVTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABSI carries a Unified Composite Score of 37.5/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin), whereas NOVTU carries 42.5/100 (HOLD) at $50.76 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While NOVTU currently prints a higher short-term Unified Composite Score (42.5/100 HOLD vs. ABSI 37.5/100 SELL), ABSI captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-9108.3% vs. N/A operating margin) and revenue trajectory (-19.6% vs. N/A YoY).
  • Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 39.3); meanwhile NOVTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABSI vs NOVTU
ABSI NASDAQ Head-to-Head Winner
Absci Corporation Common Stock
Services-Commercial Physical & Biological Research
$7.72
-8.58% 1D
Market Cap $1.6B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 3.31β · 126% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 27.0 Fund 51.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 39.3 · SMA20: $9.94 · SMA50: $9.63
NOVTU US Equity
NOVTU
Institutional Equity
$50.76
-1.05% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.70β · 65% Vol
Unified Composite Score
42.5 / 100 HOLD
Tech 30.0 Fund 45.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.0%), weak momentum, RSI 33
RSI-14: 33.1 · SMA20: $58.29 · SMA50: $59.48

6-Pillar Scorecard Institutional Category Breakdown (ABSI 4 – 0 NOVTU)

Columns: Metric · ABSI · NOVTU
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABSI
Revenue Growth (YoY) -19.6% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $1.5M N/A
Market Cap $1.6B N/A
3. Profitability & Quality ABSI
Gross Margin N/A N/A
Operating Margin -9108.3% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -58.6% N/A
4. Balance Sheet & Cash Flow ABSI
Cash Generation (TTM) -$112M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $10M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABSI
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 169.1% (15th %ile) N/A (N/A)
Put/Call OI Skew 0.57x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABSI (6) vs NOVTU (2)
Institutional Metric ABSI NOVTU Criterion Row Edge
Market Capitalization
Scale
$1.6B N/A Larger Scale ABSI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-19.6% N/A Higher Growth ABSI
Operating Margin (TTM)
Profitability
-9108.3% N/A Higher Margin ABSI
Net Profit Margin
Profitability
0.0% N/A Higher Margin ABSI
Return on Equity (ROE)
Capital Efficiency
-58.6% N/A Higher ROE ABSI
52-Week Range Position
Momentum
53% ($2–$13) 11% ($48–$77) Stronger Trend ABSI
Beta / 30D Volatility
Risk Regime
3.31β · 126% Vol 1.70β · 65% Vol Lower Realized Risk NOVTU
Unified Institutional Score
Composite Signal
37.5 / 100 (SELL) 42.5 / 100 (HOLD) Higher Composite NOVTU
Trailing 12M Revenue (USD)
Operating Scale
$1.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$112M ($10M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABSI +2.85 pp
ABSI: -6.36% · NOVTU: -9.21%
3M Horizon ABSI +10.63 pp
ABSI: -16.4% · NOVTU: -27.03%
6M Horizon ABSI +63.03 pp
ABSI: +39.44% · NOVTU: -23.59%
1Y Horizon ABSI +193.1 pp
ABSI: +192.61% · NOVTU: -0.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABSI vs NOVTU. Trailing 12-month operating profitability (ABSI -9108.3% vs NOVTU N/A) and valuation multiples (ABSI N/M vs NOVTU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABSI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross MarginN/A
Op. Margin-9108.3%
ROE / Fwd P/E-58.6% · N/M
NOVTU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABSI BREAKDOWN
97d in phase · OBV NEUTRAL
Current IV 169.1%
IV Percentile 15th %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NOVTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NOVTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABSI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and -9108.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NOVTU Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABSI vs NOVTU Key Questions & Quantitative Answers

As of Nov 16, 2026, Absci Corporation (ABSI) is the stronger overall head-to-head candidate over NOVTU (NOVTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ABSI carries a Unified Composite Score of 37.5/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin), whereas NOVTU carries 42.5/100 (HOLD) at $50.76 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While NOVTU currently prints a higher short-term Unified Composite Score (42.5/100 HOLD vs. ABSI 37.5/100 SELL), ABSI captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-9108.3% vs. N/A operating margin) and revenue trajectory (-19.6% vs. N/A YoY). Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 39.3); meanwhile NOVTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABSI leads the Growth & Scale pillar: ABSI posts -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin), compared with NOVTU at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABSI generates $1.5M in USD-normalized revenue versus N/A for NOVTU. In operating R&D and SG&A reinvestment, ABSI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NOVTU.

ABSI and NOVTU trade at balanced relative valuation multiples. ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NOVTU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABSI (-58.6% ROE) versus NOVTU (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.31β · 126% Vol realized risk). By comparison, NOVTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.70β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.